Medical Training AICombination GLP-1 Therapy
Work through the clinical reasoning behind combining GLP-1 agonists with other agents, including rationale, sequencing, and safety monitoring.
What this track covers
This track covers strategies for pairing GLP-1 receptor agonists with agents such as phentermine, metformin, or SGLT2 inhibitors, and reviews multi-drug regimens considered in treatment-resistant obesity. It focuses on the reasoning behind combination selection, complementary mechanisms, and the safety monitoring these regimens require.
What you will practice
- Weighing when a combination approach is appropriate versus GLP-1 monotherapy
- Reasoning through complementary mechanisms across drug classes
- Sequencing and adjusting therapy as agents are added
- Screening for drug interactions and contraindications before adding an agent
- Building a monitoring plan for patients on multi-drug regimens
Simulator scenario
A patient with obesity and inadequate response to GLP-1 monotherapy presents for a follow-up visit to discuss adding a second agent, requiring the clinician to weigh options, check for interactions, and set a monitoring plan.
Board question topics
- Rationale for combining GLP-1 agonists with other agents
- Mechanism-based drug interaction screening
- Monitoring parameters for multi-drug obesity regimens
- Adjusting combination therapy based on patient response
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free